Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement today regarding the importation amendment attached to the PDUFA reauthorization bill:
Common cancers in NSW are predicted to change in the next 20 years to reflect cancers affecting our migrant population, according to a new report by The Cancer Council NSW.
The Department of Biotechnology, Ministry of Science & Technology, Government of India and the International AIDS Vaccine Initiative signed an agreement today to address a major obstacle in AIDS vaccine development: the design of candidate vaccines to elicit neutralizing antibodies against HIV.
Non-profit Kaiser Permanente, one of the state’s largest health insurers, reported today a $1.2 billion revenue increase and a “profit” of $698 million up from $448 million over last year.
Focetria, a new human vaccine designed for use following the declaration of an influenza pandemic, has received European U nion approval in all 27 member states as well as Iceland and Norway.
GlaxoSmithKline [GSK: NYSE] commended the commitment of the World Health Organization (WHO) to progress plans for ensuring that the world?s most vulnerable people are protected in the event of a pandemic. Key elements of that commitment include progress being made towards the development of an H5N1 vaccine global stockpile by the WHO, and efforts to establish an additional mechanism to ensure broader access to pandemic influenza vaccine for developing world countries.
Roche announced that the European Commission has approved the use of Herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with HER2 and hormone receptor co-positive metastatic breast cancer.
Teva Pharmaceutical Industries Ltd. and Active Biotech AB announced that data from a 36-week, randomized, doubleblind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging (MRI) disease activity by 38 percent in RRMS patients and was well tolerated.
Bayer HealthCare Pharmaceuticals Inc, a U.S.-based pharmaceuticals unit of Bayer HealthCare., and Intendis Inc., a U.S.-based affiliate of Bayer Schering Pharma AG, Germany, announced today that they will jointly promote YAZ? (drospirenone/ethinyl estradiol) as a treatment for moderate acne in women who desire an oral contraceptive for birth control. The agreement came into effect on May 1, as part of an overall strategy to introduce dermatologists to the anti-acne benefits of YAZ.
Advanced Cell Technology, Inc. (OTCBB: ACTC) reported for the first time that hemangioblast precursor cells derived from human embryonic stem (hES) cells can be used to achieve vascular repair. The research, which appears today online (ahead of print) in the journal Nature Methods, by Advanced Cell Technology (ACT) and its collaborators, describes an efficient method for generating large numbers of bipotential progenitors–known as hemangioblasts–from hES cells that are capable of differentiating into blood vessels, as well as into all blood and immune cell lineages.